Evaluating the risk of drug-drug interactions with pharmacokinetic boosters: the case of ritonavir-enhanced nirmatrelvir to prevent severe COVID-19.

Girardin, F.; Manuel, O.; Marzolini, C.; Buclin, T.

doi:10.1016/j.cmi.2022.03.030

Evaluating the risk of drug-drug interactions with pharmacokinetic boosters: the case of ritonavir-enhanced nirmatrelvir to prevent severe COVID-19.

Détails

Demande d'une copie Sous embargo indéterminé.
Accès restreint UNIL
Etat: Public
Version: Final published version
Licence: Non spécifiée

ID Serval

serval:BIB_30CD844F1841

Type

Article: article d'un périodique ou d'un magazine.

Collection

Publications

Institution

UNIL/CHUV

Titre

Evaluating the risk of drug-drug interactions with pharmacokinetic boosters: the case of ritonavir-enhanced nirmatrelvir to prevent severe COVID-19.

Périodique

Clinical microbiology and infection

Auteur⸱e⸱s

Girardin F., Manuel O., Marzolini C., Buclin T.

ISSN

1469-0691 (Electronic)

ISSN-L

1198-743X

Statut éditorial

Publié

Date de publication

08/2022

Peer-reviewed

Oui

Volume

28

Numéro

8

Pages

1044-1046

Langue

anglais

Notes

Publication types: Journal Article
Publication Status: ppublish

Mots-clé

Antiviral Agents/therapeutic use, Drug Interactions, Humans, Ritonavir/pharmacokinetics, Ritonavir/therapeutic use, SARS-CoV-2, COVID-19 Drug Treatment, Antivirals, COVID-19, Drug safety, Drug-drug interactions, Nirmatrelvir, Pharmacokinetic boosters, Ritonavir

URN

urn:nbn:ch:serval-BIB_30CD844F18415

OAI-PMH

oai:serval.unil.ch:BIB_30CD844F1841

DOI

10.1016/j.cmi.2022.03.030

Pubmed

35358684

Web of science

000855302300003

Open Access

Oui